Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2355 | Metacognitive therapy and work-focused interventions Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
Common mental health disorders such as anxiety and depression are leading causes of sickness absence and disability in Norway. Despite tremendous costs for individual and society, effective treatment is lacking. Mental health interventions do not typically target work situation, despite its importance for patient well-being. On a policy level, effective measures are impeded by a paucity of scientific data, and programs designed to address the issue such as Faster Return to Work ("Raskere tilbake") lack evaluation. The present project will test the effectiveness of Metacognitive therapy and work-focused interventions for reducing sick leave in patients with common mental disorders.
Description: data from National registers
Measure: Changes in degree of sick leave Time: From 2 years prior to intervention - to 4 years after interventionDescription: data from patients self-report
Measure: Changes in degree of sick leave Time: From 2 years prior to intervention - to 4 years after interventionDescription: Changes in depressive symptoms measured by Beck Anxiety Inventory (BAI)
Measure: Changes in anxiety symptoms Time: From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-upDescription: Changes in depressive symptoms measured by Beck Depression Inventory II (BDI-II)
Measure: Changes in depressive symptoms Time: From pre treatment, to post treatment (12 weeks), 6 months 1 year follow-upDescription: Changes in metacognitions symptoms measured by the Metacognitions Questionnaire 30 (MCQ-30)
Measure: Changes in metacognitions Time: From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-upDescription: Changes in symptoms measured by Subjective Health Complaints
Measure: Changes in subjective health complaints Time: From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-upDescription: Changes in measured Negative Acts Questionnaire
Measure: Changes in bullying and victimisation at work Time: From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-upDescription: Changes measured with Return to work self-efficacy
Measure: Changes in self-efficacy Time: From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-upDescription: Changes measured with The resilience scale for adults (RSA)
Measure: Changes in resilience Time: From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-upDescription: Changes measured with EQ-5D-5L
Measure: Changes in quality of life Time: From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-upDescription: Diagnostic evaluations using MINI - International Neuropsychiatric Interview
Measure: MINI - diagnostic interview Time: From pre treatment, to post treatment (12 weeks)Description: Sub-analyses taking into consideration the onset of Covid-19 in Norway by mid March 2020
Measure: Secondary analysis related to the onset of Covid-19 Time: From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports